The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.
16 week, between-subject, double-blind, randomized clinical trial (RCT) with doxazosin (16 mg, or maximum tolerated dose, MTD) compared to placebo in 184 treatment seeking individuals with AUD
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
184
Brown University
Providence, Rhode Island, United States
Alcohol consumption
Number of drinks per week (DPW) in naturalistic condition as measured by the timeline follow-back (TLFB)
Time frame: 6 weeks
Alcohol craving
We will measure alcohol craving using the Alcohol Craving Questionnaire (ACQ) after a cue-reactivity
Time frame: one day
Alcohol craving
Alcohol craving in naturalistic condition will be measured using craving the Obsessive Compulsive Drinking Scale (OCDS)
Time frame: six weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.